Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.94 USD | -2.03% | -4.09% | -5.18% |
Financials (USD)
Sales 2024 * | 464M | Sales 2025 * | 553M | Capitalization | 1.92B |
---|---|---|---|---|---|
Net income 2024 * | 138M | Net income 2025 * | 186M | EV / Sales 2024 * | 3.15 x |
Net cash position 2024 * | 459M | Net cash position 2025 * | 682M | EV / Sales 2025 * | 2.23 x |
P/E ratio 2024 * |
14
x | P/E ratio 2025 * |
10.6
x | Employees | 167 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.59% |
Latest transcript on Catalyst Pharmaceuticals, Inc.
1 day | +3.30% | ||
1 week | -3.78% | ||
Current month | +1.50% | ||
1 month | +13.38% | ||
3 months | -5.90% | ||
6 months | +33.69% | ||
Current year | -3.21% |
Managers | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 01-12-31 |
Richard Daly
CEO | Chief Executive Officer | 62 | 15-02-18 |
Michael Kalb
DFI | Director of Finance/CFO | 53 | Dec. 31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 01-12-31 |
Donald Denkhaus
BRD | Director/Board Member | 78 | 15-02-18 |
David Tierney
BRD | Director/Board Member | 60 | 02-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.05% | 29 M€ | -0.55% | ||
0.32% | 26 M€ | -0.05% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 15.94 | -2.03% | 1 171 474 |
24-03-27 | 16.27 | +3.30% | 1,471,658 |
24-03-26 | 15.75 | -0.69% | 828,267 |
24-03-25 | 15.86 | +0.83% | 1,085,212 |
24-03-22 | 15.73 | -5.35% | 948,460 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.21% | 1.92B | |
+0.44% | 90.27B | |
+10.00% | 44.05B | |
-16.40% | 31.45B | |
+44.42% | 23.35B | |
-8.10% | 16.72B | |
-25.64% | 15.09B | |
-9.03% | 12.82B | |
-9.37% | 11.95B | |
+98.58% | 7.67B |